Not Yet RecruitingPhase 1ACTRN12605000051640
A safety study of autologous mesenchymal precursor cells (MPCs) in the management of delayed healing tibial fractures requiring secondary surgical intervention to promote fracture union.
A safety study of autologous mesenchymal precursor cells in the management of delayed healing tibial fractures requiring secondary surgical intervention to promote fracture union.
Sponsor
Mesoblast
Enrollment
10 participants
Start Date
Aug 3, 2006
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and females
Plain Language Summary
Simplified for easier understanding
This safety study tests whether injecting a patient's own mesenchymal precursor cells (a type of stem cell) at the site of a tibial (shinbone) fracture can help it heal when the fracture is delayed or has not united. It is for people with specific types of tibial fractures that require additional surgery to promote healing.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Surgery and administration of MPCs
Surgery and administration of MPCs
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000051640